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Abstract
Background: Multicentric Castleman's disease (MCD) is a rare disease, but is more frequent in
AIDS patients. MCD has only been reported twice before in patients receiving immunosuppressive
therapy after renal transplantation, and never in patients receiving immunosuppressive therapy
without transplantation. About half of the cases of MCD are human herpesvirus 8 (HHV8) –
related, in contrast to Kaposi's sarcoma, a more common complication arising after
immunosuppression, where the virus is found in virtually all cases.
Case presentation: We report a HIV-1 negative, non-transplant patient who developed HHV8-
associated multicentric Castleman's disease and Kaposi's sarcoma after 17 years of
immunosuppressive treatment with cyclosporin A for a minimal change nephropathy.
Chemotherapy with liposomal doxorubicin resolved both symptoms of multicentric Castleman's
disease and Kaposi's sarcoma in this patient. A concomitant decline in the HHV8 viral load in
serum/plasma, as determined by a quantitative real-time PCR assay, was observed.
Conclusions: Multicentric Castleman's disease can be a complication of cyclosporin A treatment.
Both multicentric Castleman's disease and Kaposi's sarcoma in this patient were responsive to
liposomal doxorubicin, the treatment of choice for Kaposi's sarcoma at the moment, again
suggesting a common mechanism linking both disorders, at least for HHV8-positive multicentric
Castleman's disease and Kaposi's sarcoma.
HHV8 viral load measurements can be used to monitor effectiveness of therapy.
Background
Castleman's disease, also called angiofollicular or giant
lymph node hyperplasia, is a clinically heterogeneous
entity that can be either localized (unicentric), or multi-
centric. The unicentric form, histopathologically
described as the hyaline-vascular subtype, is more com-
mon, is not associated with HHV8-infection, and can
mostly be treated effectively with radiotherapy or surgery
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as it presents as a solitary mass [1]. The multicentric form
is less well understood: it is an atypical lymphoprolifera-
tive disorder of a plasma cell type, and is related to
immune dysfunction. A mixture of both hyaline-vascular
and plasma-cell variants can also be found [2]. Patients
with MCD often develop malignancies like Kaposi's sar-
coma and non-Hodgkin's lymphoma [2].
Human herpesvirus 8 (HHV8, or Kaposi's sarcoma-associ-
ated herpesvirus) infection is present in nearly 100% of
multicentric Castleman's disease (MCD) cases associated
with HIV-1 infection, and in about 50% of cases that are
HIV-1 negative [3,4]. Recently, it has been proposed that
HHV8-associated MCD is histologically distinct from
HHV8-negative MCD [5,6]. Besides MCD and KS, HHV8
is also involved in a third disorder called primary effusion
lymphoma (PEL). Interestingly, the HHV8-infected cells
in MCD and PEL are of the B-cell lineage [7], while HHV8-
infected cells in KS are presumably endothelial cells with
macrophage characteristics [8].
Clinically, HHV8-positive MCD is more aggressive, and
has a poor prognosis with a median survival of less than
30 months [2,4,9,10]. MCD, whether or not HHV8-asso-
ciated, is generally treated with combination chemother-
apy (CHOP) and steroids [11].
Case presentation
In August 2002, a 38-year old homosexual, HIV-negative
Dutch male was admitted to our hospital with high fever,
night sweats, dyspnoea, coughing, weakness, hepat-
osplenomegaly, peripheral lymphadenopathy and
oedema after returning from a holiday in Spain. Medical
history revealed a minimal change nephropathy, for
which he had been taking cyclosporin A (Neoral) for the
past 17 years (5 mg/kg per day). Laboratory analysis
revealed anaemia (haemoglobin = 4.6 mmol/l), thrombo-
cytopenia (101 × 109/L), normal WBC count and differen-
tial, renal failure (creatinine = 218 µmol/l),
hypoalbuminemia (24 g/l), and elevated CRP (133 mg/l).
Diagnostic assays for HIV-1 were performed and repeat-
edly negative. No acute CMV or EBV infection was
detected (by serology and PCR analysis). Chest X-ray
showed interstitial infiltrates, however, bronchoalveolar
lavage did not reveal an infectious agent. CT-scans
revealed hepatosplenomegaly and enlarged abdominal
lymph nodes. A bone marrow biopsy showed an active
haematopoiesis in all cell lineages without any
abnormalities.
Histological examination of an axillary lymph node
biopsy (Fig. 1A) showed a multifocal proliferation of
spindle cells. The diagnosis of Kaposi's sarcoma was con-
firmed by positive staining of these spindle cells with anti-
bodies to factor VIII-related antigen (not shown) and
HHV8 (Fig. 1B). The remainder of the lymph node
showed partly involuted germinal centres, surrounded by
small lymphocytes. A number of these lymphocytes also
stained positive for HHV8, as seen in multicentric Castle-
man's disease (Fig. 1C). The clinical syndrome and the
histological findings were compatible with KS and MCD
caused by a HHV8 infection in a long-term immunocom-
promised patient. HHV8 DNA load in serum or plasma
was determined by real-time quantitative PCR [12], and
was found to increase from 9.0 × 105 copies/ml at the time
of admission to 6.3 × 106 copies/ml before treatment start
(Fig. 2).
Despite discontinuation of cyclosporin A and supportive
care his clinical condition deteriorated with fever, dysp-
noea, oedema and exhaustion, together with the develop-
ment of oral and facial KS lesions. Liposomal doxorubicin
(Caelyx 20 mg/m2) was initiated at three-week intervals,
ten days after discontinuation of Neoral. Although Caelyx
is nowadays the drug of choice to treat KS [13], it has not
been reported as a treatment for MCD, however, it has
been shown to lower the HHV8 load [14], suggesting it
may also have an effect on other HHV8-related diseases.
HHV8 viral load has earlier been associated with clinical
outcome in both KS and MCD, whereby a decrease in viral
load measured in blood was linked to a favourable out-
come [15-18], and an increase in HHV8 viral load with
exacerbations in clinical symptoms [19-21].
Within two weeks after treatment start he clinically
improved with disappearance of hepatomegaly, lymphad-
enopathy, and pulmonary infiltrates, and all laboratory
parameters became normal. Simultaneously, the HHV8
load dropped to 7.4 × 104 copies/ml, but started to rise
again after two weeks to 1.7 × 105 copies/ml, with recur-
rence of his clinical symptoms. After the second course of
Caelyx, the HHV8 load decreased to 1.1 × 103 copies/ml.
The treatment response was again transient and three
weeks later his HHV8 load had risen to 2.4 × 104 copies/
ml. After the third Caelyx treatment the viral load was per-
manently reduced to around the detection limit of the
assay (1.66 × 102 copies/ml). Another three courses of
Caelyx were given. Fourteen months later he is still disease
free without fever, lymphadenopathy or KS lesions.
Immunosuppressive therapy with cyclosporin A was dis-
continued, which is expected to contribute to the ongoing
remission.
KS specifically occurs under cyclosporin A therapy in
about 0.87% of renal transplant patients [22]. MCD how-
ever, is rarely seen under immunosuppressive treatment
after transplantation [23,24], and has never been reported
before in non-transplant patients treated with cyclosporin
A [25].BMC Blood Disorders 2003, 3 http://www.biomedcentral.com/1471-2326/3/3
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Retrospective analysis of the stored serum samples with
the Diavir HHV8 peptide mix ELISA (Biotrin Interna-
tional, Dublin, Ireland) showed that this patient was
already IgG antibody-positive with very high titres at pres-
entation (result not shown), making an acute HHV8
infection unlikely. As expected, all subsequent serum sam-
ples were also HHV8 antibody-positive (results not
shown). So, the relatively late development of MCD in
this homosexual patient (arising only after 17 years of
cyclosporin treatment) is most probable due to a reactiva-
tion of an existing HHV8 infection. However, the HHV8
infection might be younger than the start of cyclosporin
treatment 17 years ago, and as no earlier serum samples
were available, it is difficult to estimate the time period
elapsed between HHV8 infection and development of
MCD. In The Netherlands, HHV8 infections are more
common among men having sex with men than in the
general population or any other risk group [26], making
homosexuality the main risk factor for HHV8 acquisition,
with iatrogenic immunosuppression being the risk factor
for subsequent MCD development in this patient.
In general MCD has a poor prognosis with a rapidly fatal
clinical course [4,9,10], therefore it is remarkable that in
this case the patient responded well to Caelyx therapy,
showing a concomitant decline of the HHV8 load in
blood. Interestingly, a case of EBV-negative post-trans-
plantation lymphoproliferative disorder (PTLD), attrib-
uted to a transplantation-associated HHV8-infection in a
17 year-old boy, responded only to a combination of
Microscopic morphology of representative lymph node sections and immunohistochemical detection of HHV8 infection Figure 1
Microscopic morphology of representative lymph node sections and immunohistochemical detection of HHV8 infection. A: 
Histology of the axillary lymph node showing proliferation of spindle cells (lower left) and partly involuted germinal center, sur-
rounded by small lymphocytes (upper right). B: HHV8 positive spindle cells. C: HHV8 positive lymphocytes in the follicular 
mantle zone.
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liposomal daunorubicin and alpha-interferon [27]. EBV-
positive PTLD's, but not EBV-negative cases, have been
found to respond to withdrawal of immunosuppression
alone [27]. Possibly, HHV8-associated lymphoprolifera-
tive disorders share common features, and require similar
treatment.
Conclusions
MCD can arise as a complication of cyclosporin treat-
ment. HHV8 viral load measurements are indicative of
effectiveness of therapy in HHV8-associated MCD.
MCD, as well as KS, in this patient was responsive to lipo-
somal doxorubicin, the treatment of choice for KS at the
moment, again suggesting a common mechanism linking
both disorders.
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HHV8 DNA load of consecutive serum/plasma samples from the case measured with real-time PCR Figure 2
HHV8 DNA load of consecutive serum/plasma samples from the case measured with real-time PCR. Arrows indicate the 
chemotherapy courses. All samples were HHV8 IgG antibody-positive.
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